651 related articles for article (PubMed ID: 17875707)
1. Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors.
Liu JC; Deng T; Lehal RS; Kim J; Zacksenhaus E
Cancer Res; 2007 Sep; 67(18):8671-81. PubMed ID: 17875707
[TBL] [Abstract][Full Text] [Related]
2. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
3. Rassf3 is responsible in part for resistance to mammary tumor development in neu transgenic mice.
Jacquemart IC; Springs AE; Chen WY
Int J Oncol; 2009 Feb; 34(2):517-28. PubMed ID: 19148488
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo antisense-mediated growth inhibition of a mammary adenocarcinoma from MMTV-neu transgenic mice.
Sacco MG; Barbieri O; Piccini D; Noviello E; Zoppé M; Zucchi I; Frattini A; Villa A; Vezzoni P
Gene Ther; 1998 Mar; 5(3):388-93. PubMed ID: 9614559
[TBL] [Abstract][Full Text] [Related]
5. Preferential killing of breast tumor initiating cells by N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine/tesmilifene.
Deng T; Liu JC; Pritchard KI; Eisen A; Zacksenhaus E
Clin Cancer Res; 2009 Jan; 15(1):119-30. PubMed ID: 19118039
[TBL] [Abstract][Full Text] [Related]
6. The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis.
Vaillant F; Asselin-Labat ML; Shackleton M; Forrest NC; Lindeman GJ; Visvader JE
Cancer Res; 2008 Oct; 68(19):7711-7. PubMed ID: 18829523
[TBL] [Abstract][Full Text] [Related]
7. MMTV promoter hypomethylation is linked to spontaneous and MNU associated c-neu expression and mammary carcinogenesis in MMTV c-neu transgenic mice.
Zhou H; Chen WD; Qin X; Lee K; Liu L; Markowitz SD; Gerson SL
Oncogene; 2001 Sep; 20(42):6009-17. PubMed ID: 11593408
[TBL] [Abstract][Full Text] [Related]
8. The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis.
Rudolph-Owen LA; Chan R; Muller WJ; Matrisian LM
Cancer Res; 1998 Dec; 58(23):5500-6. PubMed ID: 9850086
[TBL] [Abstract][Full Text] [Related]
9. Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors.
Cho RW; Wang X; Diehn M; Shedden K; Chen GY; Sherlock G; Gurney A; Lewicki J; Clarke MF
Stem Cells; 2008 Feb; 26(2):364-71. PubMed ID: 17975224
[TBL] [Abstract][Full Text] [Related]
10. Use of mouse mammary tumour virus (MMTV)/neu transgenic mice to identify genes collaborating with the c-erbB-2 oncogene in mammary tumour development.
Jolicoeur P; Bouchard L; Guimond A; Ste-Marie M; Hanna Z; Dievart A
Biochem Soc Symp; 1998; 63():159-65. PubMed ID: 9513720
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinases play an active role in Wnt1-induced mammary tumorigenesis.
Blavier L; Lazaryev A; Dorey F; Shackleford GM; DeClerck YA
Cancer Res; 2006 Mar; 66(5):2691-9. PubMed ID: 16510589
[TBL] [Abstract][Full Text] [Related]
12. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer.
Howe LR; Subbaramaiah K; Patel J; Masferrer JL; Deora A; Hudis C; Thaler HT; Muller WJ; Du B; Brown AM; Dannenberg AJ
Cancer Res; 2002 Oct; 62(19):5405-7. PubMed ID: 12359744
[TBL] [Abstract][Full Text] [Related]
13. Lack of ductal development in the absence of functional estrogen receptor alpha delays mammary tumor formation induced by transgenic expression of ErbB2/neu.
Hewitt SC; Bocchinfuso WP; Zhai J; Harrell C; Koonce L; Clark J; Myers P; Korach KS
Cancer Res; 2002 May; 62(10):2798-805. PubMed ID: 12019156
[TBL] [Abstract][Full Text] [Related]
14. Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer.
Bentires-Alj M; Neel BG
Cancer Res; 2007 Mar; 67(6):2420-4. PubMed ID: 17347513
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice.
Zinser GM; Welsh J
Carcinogenesis; 2004 Dec; 25(12):2361-72. PubMed ID: 15333467
[TBL] [Abstract][Full Text] [Related]
16. Challenge with mammary tumor cells expressing MHC class II and CD80 prevents the development of spontaneously arising tumors in MMTV-neu transgenic mice.
Jabrane-Ferrat N; Campbell MJ; Esserman LJ; Peterlin BM
Cancer Gene Ther; 2006 Nov; 13(11):1002-10. PubMed ID: 16841083
[TBL] [Abstract][Full Text] [Related]
17. Alcohol promotes mammary tumor development via the estrogen pathway in estrogen receptor alpha-negative HER2/neu mice.
Wong AW; Dunlap SM; Holcomb VB; Nunez NP
Alcohol Clin Exp Res; 2012 Apr; 36(4):577-87. PubMed ID: 21981381
[TBL] [Abstract][Full Text] [Related]
18. Involvement of tyrosine phosphorylation of p185(c-erbB2/neu) in tumorigenicity induced by X-rays and the neu oncogene in human breast epithelial cells.
Kang KS; Sun W; Nomata K; Morita I; Cruz A; Liu CJ; Trosko JE; Chang CC
Mol Carcinog; 1998 Apr; 21(4):225-33. PubMed ID: 9585252
[TBL] [Abstract][Full Text] [Related]
19. CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling.
Lo PK; Kanojia D; Liu X; Singh UP; Berger FG; Wang Q; Chen H
Oncogene; 2012 May; 31(21):2614-26. PubMed ID: 21996747
[TBL] [Abstract][Full Text] [Related]
20. Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer.
Kondratyev M; Kreso A; Hallett RM; Girgis-Gabardo A; Barcelon ME; Ilieva D; Ware C; Majumder PK; Hassell JA
Oncogene; 2012 Jan; 31(1):93-103. PubMed ID: 21666715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
